|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide region of human AEBP1.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS with 2% sucrose|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||Assay-dependent|
|Western Blot (WB)||0.2-5 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Western Blot (WB)||See 1 publications below|
PA1-24440 detects AEBP1 in Human samples.
PA1-24440 has been successfully used in Western Blot and Immnuohistochemistry (paraffin-embedded sections) procedures. By Western blot, PA1-24440 detects a ~ 131 kDa protein representing AEBP1 in HepG2cell lysate.
PA1-24440 immunogen corresponds to Polyclonal antibody from rabbits immunized with a synthetic peptide region of human AEBP1.
The adipocyte enhancer binding protein 1 (AEBP1) is a transcriptional repressor with carboxypeptidase (CP) activity. This protein binds to a regulatory sequence, adipocyte enhancer 1 (AE-1), located in the proximal promoter region of the adipose P2 (aP2) gene, which encodes the adipocyte fatty-acid binding protein. It is characterized as a member of the regulatory B-like CP family. This protein seems to be activated by a novel mechanism, whereby the direct binding of DNA enhances its protease activity. AEBP1 may play a role in differentiated vascular smooth muscle cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease.
PA1-24440 was used in western blot to develop a novel technology to identify plasma biomarkers for cardiovascular disease
|Addona TA,Shi X,Keshishian H,Mani DR,Burgess M,Gillette MA,Clauser KR,Shen D,Lewis GD,Farrell LA,Fifer MA,Sabatine MS,Gerszten RE,Carr SA||Nature biotechnology (29:635)||2011|